Pfizer sinks following early breast cancer failure

1 June 2020
pfizer_ny_large

Shares in New York-based pharma giant Pfizer (NYSE: PFE) were down over 6% ahead of the opening bell in New York, following a trial miss in breast cancer.

A futility analysis from independent data monitors showed the Phase III PALLAS study of Ibrance (palbociclib) would likely miss its primary endpoint of invasive disease-free survival (iDFS).

While the therapy has been met with great success in breast cancer following its launch in 2015, the results could have unlocked access to a multi-billion-dollar opportunity treating patients earlier on in the disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical